Wegovy (Semaglutide) Weight Loss Injection USA

Product Description: Wegovy (Semaglutide) Weight Loss Injection – USA

Wegovy® (Semaglutide) is a once‑weekly prescription injection approved in the USA for long‑term weight management in adults and adolescents with obesity, or adults who are overweight with weight‑related health problems. It is used alongside a reduced‑calorie diet and increased physical activity, and recent FDA updates (March 2026) include expanded dosing options up to 7.2 mg

What It Is

• Brand Name: Wegovy®
• Generic Name: Semaglutide
• Drug Class: GLP‑1 receptor agonist
• Form: Prefilled, single‑dose pens for subcutaneous injection (under the skin)
• Dosing Schedule: Once weekly self‑administered injection

Available Strengths

• 0.25 mg / 0.5 mL
• 0.5 mg / 0.5 mL
• 1 mg / 0.5 mL
• 1.7 mg / 0.75 mL
• 2.4 mg / 0.75 mL
• New high‑dose option: 7.2 mg (FDA approved March 2026)

Indications

• Weight loss & long‑term weight management in:
  • Adults with obesity (BMI ≥30)
  • Adults who are overweight (BMI ≥27) with at least one weight‑related condition (e.g., hypertension, type 2 diabetes, high cholesterol)
  • Adolescents ≥12 years old with obesity
• Cardiovascular protection: Reduces risk of major adverse CV events (heart attack, stroke, CV death) in adults with obesity/overweight and established cardiovascular disease.
• Liver health: Approved for metabolic dysfunction‑associated steatohepatitis (MASH) in adults with moderate to advanced fibrosis.

How It Works

• Mimics GLP‑1 hormone, regulating appetite and food intake.
• Helps patients feel fuller longer, reducing calorie consumption.
• Clinical trials show average weight loss of ~21% at 72 weeks with the 7.2 mg dose when combined with diet and exercise.

⚠️ Safety & Warnings

• Boxed Warning: Risk of thyroid C‑cell tumors (seen in rodents; human relevance unknown).
• Contraindications:
  • Personal/family history of medullary thyroid carcinoma (MTC)
  • Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Serious hypersensitivity to semaglutide or ingredients
• Common Side Effects: Nausea, vomiting, diarrhea, constipation, abdominal pain.
• Serious Risks: Pancreatitis, gallbladder disease, kidney injury, low blood sugar (especially with diabetes medications).

📦 Key Selling Points (USA Market)

• FDA‑approved for multiple indications including obesity, CV risk reduction, and MASH.
• Convenient once‑weekly injection with easy‑to‑use pen device.
• Clinically proven weight loss results (up to 21% body weight reduction).
• Expanded dosing options allow personalized treatment.
• Trusted manufacturer: Novo Nordisk.